In vivo and ex vivo evidence in MM has demonstrated that activation of Notch3 in osteocytes contributes to osteolytic disease by the overexpression of RANKL and the osteoblast inhibitor sclerostin. The gene discussed is NOTCH3; the disease is Miyoshi myopathy.